Exosomes released by imatinib-resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib-sensitive cells in the presence of imatinib
Hrdinova T, Toman O, Dresler J, Klimentova J, Salovska B, Pajer P, Bartos O, Polivkova V, Linhartova J, Machova Polakova K, Kabickova H, Brodska B, Krijt M, Zivny J, Vyoral D, Petrak J, Hrdinova T, Toman O, Dresler J, Klimentova J, Salovska B, Pajer P, Bartos O, Polivkova V, Linhartova J, Machova Polakova K, Kabickova H, Brodska B, Krijt M, Zivny J, Vyoral D, Petrak J. Exosomes released by imatinib-resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib-sensitive cells in the presence of imatinib. International Journal Of Oncology 2020, 58: 238-250. PMID: 33491750, DOI: 10.3892/ijo.2020.5163.Peer-Reviewed Original ResearchMeSH KeywordsApoptosisCD146 AntigenCD36 AntigensCell Line, TumorCell SurvivalDrug Resistance, NeoplasmExosomesFusion Proteins, bcr-ablHumansImatinib MesylateK562 CellsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMembrane ProteinsProtein Kinase InhibitorsRNA-Binding ProteinsConceptsTyrosine kinase inhibitorsChronic myeloid leukemiaImatinib-resistant K562 cellsCML therapyImatinib-sensitive K562 cellsDrug resistanceK562 cellsTargeted CML therapySubset of patientsLess common mutationsSpecific tyrosine kinase inhibitorTKI drug resistanceInterferon-induced transmembrane protein 3Presence of imatinibQuality of lifeMalignant hematopoietic disordersPotential diagnostic markerFlow cytometric analysisBCR-ABL1 geneConstitutive kinase activityCell surface markersLabel-free quantification proteomics analysisMutation-independent mechanismTransmembrane protein 3Development of resistance